Danaher to Acquire Masimo for $9.9B in Major Medical Tech Deal

Danaher Corporation has agreed to acquire US medical technology company Masimo Corporation for approximately $9.9 billion, marking a significant consolidation in the medical technology sector. The deal values Masimo at $180 per share, representing a nearly 40% premium over its closing price on February 13, 2026.

The acquisition, announced on February 17, 2026, is expected to close in the second half of 2026, subject to customary regulatory approvals and other closing conditions. This strategic move by Danaher aims to strengthen its position in the medical technology market by adding Masimo's innovative patient monitoring and diagnostic solutions to its portfolio.

Masimo, headquartered in Irvine, California, is known for its non-invasive monitoring technologies, including pulse oximetry and other patient monitoring systems used in hospitals and healthcare settings worldwide. The company has been a pioneer in developing technologies that improve patient outcomes and reduce healthcare costs through more accurate and continuous monitoring.

Danaher, a global science and technology innovator, has been actively expanding its healthcare portfolio through strategic acquisitions. This deal represents one of the largest in the medical technology space in recent years and underscores the growing consolidation trend in the healthcare industry as companies seek to leverage complementary technologies and expand their market reach.

The premium offered by Danaher reflects the strategic value of Masimo's technology portfolio and its strong market position. Masimo's shares surged following the announcement, reflecting investor approval of the price and the certainty of the transaction.

This acquisition comes amid a broader wave of consolidation in the healthcare technology sector, driven by the need for integrated solutions, economies of scale, and the growing importance of data-driven healthcare. The deal also highlights the continued interest in medical technology companies that offer innovative solutions for patient monitoring and care delivery.

Industry analysts suggest that the combination of Danaher's broad healthcare platform with Masimo's specialized monitoring technologies could create significant synergies and accelerate innovation in patient care. The transaction is expected to be accretive to Danaher's earnings in the first full year following closing.

For Masimo shareholders, the deal provides immediate value at a substantial premium to recent trading levels. For Danaher, it represents an opportunity to expand its medical technology offerings and strengthen its competitive position in a rapidly evolving healthcare landscape.

The medical technology sector has seen increased M&A activity as companies seek to address growing healthcare challenges, including the need for more efficient patient monitoring, better diagnostic tools, and integrated healthcare solutions. This deal between Danaher and Masimo is likely to be viewed as a significant milestone in this ongoing trend of consolidation and innovation in healthcare technology.

As the transaction moves toward closing in H2 2026, both companies will focus on integration planning to ensure a smooth transition and realization of the anticipated benefits from the combination of their respective capabilities and technologies.